Novartis’ Blockbuster Hopeful Leqvio Faces Perils Of Medicare’s Pricing Policy On Small Molecules
Medicare’s pending price negotiation program could impact the longevity of the Part B cholesterol drug Leqvio. Novartis CEO Vas Narasimhan notes the upcoming redesign of the Part D benefit could boost pricing pressure on Kisqali.
You may also be interested in...
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
As Republicans expand their power in Congress, experts weigh in on prospects for significant changes to the Medicare price negotiation law and what the GOP might do to hamper implementation of the program.
Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.